Phase II Clinical Study of JTE-052A - Dose finding study in patients with atopic dermatitis

Trial Profile

Phase II Clinical Study of JTE-052A - Dose finding study in patients with atopic dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs JTE 052 (Primary) ; Tacrolimus
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Japan Tobacco
  • Most Recent Events

    • 28 Sep 2017 Primary endpoint (The percent change in modified Eczema Area Severity Index (m-EASI) score) has been met, according to the results published in the British Journal of Dermatology.
    • 28 Sep 2017 Results published in the British Journal of Dermatology
    • 15 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top